Revlimid
- FLASCO
- March 10, 2015
- Drugs
Revlimid
The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp’s cancer drug Revlimid to include newly diagnosed patients with multiple myeloma. Previously the drug was only approved for patients who had received at least one previous therapy. Physicians in the United States have long been prescribing Revlimid for new patients on an “off-label” basis, but the company had not been allowed to promote its use in this population. The FDA’s action means Celgene can market Revlimid, in combination with a different drug, dexamethasone, as a treatment for all multiple myeloma patients and helps validate the company’s premise that treating patients earlier and for a longer period of time increases progression-free survival. Click Here to Read More
